Literature DB >> 3999018

Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.

N Terao, D D Shen.   

Abstract

Previous in vivo studies have shown that the presystemic clearance of p.o.-administered levo-isomer of propranolol is inhibited in rats with uranyl nitrate-induced acute renal failure. A series of steady-state single-pass rat liver perfusion studies were performed to explore the probable mechanism of the observed metabolic inhibition. When livers from normal rats were perfused with blood perfusate prepared from normal donor animals, a high extraction ratio (Eh) of 0.974 +/- 0.005 (mean +/- S.D.) was observed at an influent I-propranolol concentration of 400 ng/ml, i.e., only 2.6% of drug entering the liver escaped single-pass extraction. The extraction of I-propranolol was significantly lower (i.e., Eh = 0.906 +/- 0.017) when livers isolated from uranyl nitrate-induced renal failure rats were perfused with uremic blood; such that there was an approximate 3-fold increase in the amount of drug escaping single-pass extraction (i.e., from 2.6 to 9.4%). This difference in hepatic extraction is quantitatively consistent with the increase in p.o. systemic availability of I-propranolol observed in our previous in vivo study with the uranyl nitrate-induced renal failure rat model. When livers from normal rats were cross-perfused with uremic blood, extraction of I-propranolol was depressed to almost the same level (i.e., Eh = 0.927 +/- 0.009) as when livers from renal failure animals were perfused with uremic blood. In contrast, livers from renal failure rats cross-perfused with normal blood exhibited comparable extraction for I-propranolol (Eh = 0.970 +/- 0.010) as normal livers perfused with normal blood.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3999018

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

Review 2.  Principles of drug administration in renal insufficiency.

Authors:  Y W Lam; S Banerji; C Hatfield; R L Talbert
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 3.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

4.  Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators.

Authors:  Carl Guévin; Josée Michaud; Judith Naud; Francois A Leblond; Vincent Pichette
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

5.  Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450.

Authors:  Josée Michaud; Pierre Dubé; Judith Naud; Francois A Leblond; Karine Desbiens; Alain Bonnardeaux; Vincent Pichette
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

6.  The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.

Authors:  Gary J Muirhead; Keith Wilner; Wayne Colburn; Gertrude Haug-Pihale; Bernhard Rouviex
Journal:  Br J Clin Pharmacol       Date:  2002       Impact factor: 4.335

Review 7.  The effect of chronic renal failure on drug metabolism and transport.

Authors:  Albert W Dreisbach; Juan J L Lertora
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-08       Impact factor: 4.481

Review 8.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Dibromosulphophthalein: its pharmacokinetics and binding to hepatic cytosol proteins in rats with acute renal failure.

Authors:  D J Silberstein; C J Bowmer; M S Yates
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

Review 10.  Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport.

Authors:  Catherine K Yeung; Danny D Shen; Kenneth E Thummel; Jonathan Himmelfarb
Journal:  Kidney Int       Date:  2013-10-16       Impact factor: 10.612

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.